Skip to main content

Table 1 Characteristics of patients enrolled into IMPACT/COMPACT (n = 1893)

From: Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

Patients enrolled Patients enrolled Patients profiled Patients profiled enrolled on any therapeutic trials Patients profiled enrolled on genotype-matched trials
Median age (range) 59 (18–89) 58 (18–89) 58 (18–81) 58 (24–81)
Female/Male 1303/590 (59 %)/(31 %) 1166/479 (71 %)/(29 %) 205/72 (74 %)/(26 %) 64/25 (72 %)/(28 %)
Median lines of prior treatment (range) 2 (1–18) 2 (1–18) 2 (1–16) 2 (1–11)
ECOG performance status (0/1/2) 43 %/56 %/<1 % 44 %/55 %/<1 % 78 %/22 %/0 % 78 %/22 %/0 %
Median time from collection of archival tumor sample to profiling report in years (range) 1.6 (0.1-24.9) 1.7 (0.1-18.9) 1.9 (0.1-18.9)
Primary lesion/Metastatic lesion profiled 1080/560 193/84 66/23
(66 %)/(34 %) (70 %)/(30 %) (74 %)/(26 %)
Tumor types
 Breast 341 (18 %) 310 (19 %) 41/310 (13 %) 19/310 (6 %)
 Colorectal 326 (17 %) 299 (18 %) 38/299 (13 %) 18/299 (6 %)
 Gynecological 430 (23 %) 405 (25 %) 80/405 (20 %) 20/405 (5 %)
 Lung 339 (18 %) 256 (16 %) 43/256 (17 %) 18/256 (7 %)
 Genitourinary 92 (5 %) 74 (5 %) 9/74 (12 %) 4/74 (5 %)
 Pancreatobiliary 151 (8 %) 104 (6 %) 9/104 (9 %) 1/104 (1 %)
 Upper aerodigestive 115 (6 %) 102 (6 %) 8/102 (8 %) 2/102 (2 %)
 Other 99 (5 %) 81 (5 %) 17/81 (21 %) 2/81 (2 %)
 TOTAL 1893 1640 245/1640 (15 %) 84/1640 (5 %)